Your fact-checks will appear here
Available reporting shows Dr. Paul Alan Cox leads Brain Chemistry Labs and has taken L‑serine research into FDA‑approved human trials, but the sources do not explicitly show his name on Neurocept INDs...
Dr. Paul Alan Cox has steered research toward simple, low-cost interventions and diagnostics for neurodegenerative disease through his leadership at Brain Chemistry Labs, promoting L‑serine trials and...
Dr. Paul Alan Cox has led and helped initiate clinical work focused mainly on the dietary amino acid L‑serine as a potential neuroprotective therapy—trials include a Phase I safety study in ALS and la...
Dr. Paul Alan Cox has led a series of ethnobotany‑driven projects at Brain Chemistry Labs focused on neurodegenerative diseases — notably work on L‑serine as a potential neuroprotective agent and the ...
Dr. Paul Alan Cox is repeatedly identified in the available reporting as the executive director (or executive director-equivalent leader) of Brain Chemistry Labs — the research arm of the Institute fo...
Dr. Paul Alan Cox has led and been associated with multiple human clinical trials testing L‑serine for neurodegenerative diseases: a Phase I safety trial in ALS and a 125‑patient FDA‑approved Phase II...
Available reporting and organizational profiles show Dr. Paul Alan Cox has been associated with Brain Chemistry Labs and other nonprofits but the provided search results do not identify who — if anyon...
Dr. Paul Alan Cox, executive director of Brain Chemistry Labs (aka Neurocept/Brain Chemistry Labs in reporting), has led collaborations with academic and clinical partners including a Phase II FDA-app...
Dr. Paul Alan Cox is listed as a co‑author on a six‑month randomized, double‑blind Phase I trial of oral L‑serine in ALS patients that is indexed on PubMed (20 patients enrolled) . Multiple organizati...
There are claims in media and organizational materials that Dr. Paul Alan Cox has advanced L‑serine research into human trials and that his Brain Chemistry Labs has run or planned clinical studies, bu...
The available reporting does not show Dr. Paul Alan Cox holding any title at Neurocept; there is no source here linking him to that company, so his "current title at Neurocept" cannot be confirmed fro...
Available reporting shows Dr. Paul Alan Cox has led preclinical work and small clinical efforts on L‑serine through his Brain Chemistry Labs/Institute for EthnoMedicine and says he took findings to th...
Dr. Paul Alan Cox is identified in multiple outlets as the leader of Brain Chemistry Labs (also called the Institute for Ethnomedicine or Brain Chemistry Labs / The Institute for EthnoMedicine) — serv...
Dr. Paul Alan Cox’s public record shows an extensive body of peer‑reviewed publications and frequent presentations that consistently emphasize ethnobotanical drug discovery and neurodegenerative disea...
Dr. Sanjay Gupta approaches mental health as a broad public-health and brain‑health communicator, emphasizing prevention, lifestyle and access to care through media, moderation of expert forums and ed...
There is no evidence in the supplied reporting that a company or trademark named “Neurocept” is registered to, owned by, or formally connected with Dr. Paul Alan Cox or Brain Chemistry Labs; the avail...
Dr. Paul Alan Cox is a prolific ethnobotanist and researcher credited in sources with "over 180" to "over 250" scientific papers, reviews and books; he also founded the Institute for Ethnomedicine and...
Dr. Paul Alan Cox is consistently identified in the supplied reporting as the executive director of Brain Chemistry Labs / the Institute for Ethnomedicine and as an independent ethnobotanist leading a...